Timing note: Lilly reports today, Wednesday, August 5, 2026—not tomorrow. The company’s conference call is scheduled for 10:00 a.m. ET.
Lilly enters Q2 with its core question unchanged: can exceptional incretin volume growth continue to outrun price erosion? The company has already demonstrated that it can—Q1 revenue rose 56% year over year to $19.8 billion—but the bar is higher now. Investors will focus less on the headline beat and more on the durability of:
The stock closed at $1,115.72 on August 4, up roughly 31% from the April 29 close before Q1 earnings, though about 10% below its July 7 closing high. That setup suggests investors recognize Lilly’s operational strength, but will demand confirmation that growth, pricing, and pipeline momentum remain intact.
Mounjaro and Zepbound are the financial engine of Lilly.
| Product | Q1 2026 revenue | Q1 YoY growth | Q2 2025 revenue baseline |
|---|---|---|---|
| Mounjaro | $8.66B | +125% | $5.20B |
| Zepbound | $4.16B | +80% | $3.38B |
| Combined | $12.82B | — | $8.58B |
In Q1, Mounjaro and Zepbound together represented approximately 65% of company revenue. That concentration makes the underlying components of growth more important than the total sales number.
Did Mounjaro’s international expansion remain powerful after the extraordinary Q1 step-up?
Q1 ex-U.S. Mounjaro sales reached $4.4 billion, helped by substantial volume growth and China’s National Reimbursed Drug List inclusion for diabetes. Q2 needs to demonstrate that this is not merely a reimbursement-related step function, but the beginning of a sustainable international adoption curve.
Can Zepbound continue expanding despite lower net prices?
Lilly has embraced lower out-of-pocket prices and self-pay access as a way to unlock volume. The strategy appears effective: in Q1, self-pay represented about 45% of Zepbound prescriptions and roughly 55% of new prescriptions. The trade-off is clear—more access and prescriptions, but persistent pressure on realized price.
Is commercial coverage improving or simply stable?
Employer coverage remains a long-term opportunity rather than a near-term earnings driver. Lilly has indicated that its Employer Connect model should have a more meaningful impact in 2027 than in 2026.
Q1 worldwide revenue growth was driven by a 65% volume increase, partly offset by a 13% decline in realized prices. In the U.S., price was down 7%, but management said the decline would have been roughly 10% excluding a favorable one-time rebate/discount-estimate adjustment.
Lilly’s full-year framework still assumes a low-to-mid-teens price headwind. Therefore, investors should view a strong quarter that relies on temporary favorable rebate true-ups less positively than one that shows sustained prescription and patient growth with predictable net pricing.
The core earnings question: Is price erosion tracking within Lilly’s guide, and is unit-demand growth still sufficiently strong to support another upward revision?
Foundayo, Lilly’s oral GLP-1 for obesity, was broadly available in U.S. pharmacies on April 9. Q2 therefore captures its first partial commercial quarter, though the initial rollout was deliberately measured.
At the Q1 call, Lilly disclosed: - More than 20,000 patients had been treated in the early launch period; - Approximately 80% of prescriptions were from patients new to the class; - Commercial access had been confirmed at two of the three largest PBMs, effective around mid-May; - Full-scale consumer television advertising was planned for Q3.
Foundayo sales are unlikely to be the principal determinant of a Q2 beat. The investment relevance is instead in leading indicators:
The favorable interpretation would be that Foundayo reaches lower-BMI, earlier-treatment, injection-averse, and cash-pay patients—thereby increasing Lilly’s addressable population. A slower launch would not necessarily damage the long-term thesis, but it would challenge the narrative that oral GLP-1s can rapidly unlock a large incremental market.
After Q1, Lilly raised 2026 guidance to:
| 2026 guidance | Current range |
|---|---|
| Revenue | $82.0B–$85.0B |
| Non-GAAP performance margin | 47.0%–48.5% |
| Non-GAAP EPS | $35.50–$37.00 |
The Q1 revenue base was already $19.8 billion. To deliver the full-year revenue range, Lilly needs approximately $62.2 billion to $65.2 billion across Q2–Q4, or roughly $20.7 billion to $21.7 billion per quarter on average.
That is demanding, but plausible given: - Continued Mounjaro international growth; - Sustained Zepbound demand; - Further expansion of oral GLP-1 access; - July activation of the Medicare GLP-1 Bridge program, which is more relevant to second-half outlook than to Q2 revenue; - Contributions from immunology, oncology, and neuroscience launches.
Management may choose to retain conservatism because of: - Ongoing price concessions and reimbursement negotiations; - Launch investments for Foundayo and other new products; - A large R&D burden, including 42 active Phase III programs cited in Q1; - Acquired in-process R&D charges and integration costs from its active business-development program.
Lilly’s Q1 non-GAAP gross margin was 82.6%, down 90 basis points year over year, primarily due to lower realized prices. Yet non-GAAP performance margin was 50%, up about seven points year over year, reflecting operating leverage from extraordinary revenue growth.
For Q2, investors should focus on:
A high-quality result would feature revenue growth, stable-to-improving operating leverage, and guidance that demonstrates that Lilly can keep investing aggressively without compromising its longer-term margin model.
While it will not affect Q2 sales, retatrutide is increasingly important to the long-term bull case.
Recent Phase III data showed: - Up to 28.3% average weight loss at 80 weeks at the highest dose in TRIUMPH-1; - 30.3% weight loss in a treatment-extension subset; - Approximately 19% weight loss at the 4 mg dose, with discontinuations due to adverse events below the placebo rate in that study; - Improvement in obesity-related knee pain and obstructive-sleep-apnea measures.
Lilly said on July 23 that it expects to seek approval for retatrutide in early 2027. Investors should listen for clarification on the regulatory timeline, manufacturing planning, dose positioning, and the role of retatrutide relative to Zepbound and Foundayo.
One important nuance: June investor-event commentary had referenced a second-half 2026 filing timeline, while July communication pointed to early 2027. Management should be asked whether this reflects a changed timeline, a broader data package, or differing regulatory-geography assumptions.
Lilly is no longer solely an obesity story. Investors should look for continued momentum in:
These products matter because they diversify Lilly’s revenue base and support the argument that the company can remain a superior-growth large-cap pharma company even outside cardiometabolic health.
The Medicare obesity-drug access program activated in July, after Q2 ended. It should not materially affect reported Q2 sales, but management’s early commentary on physician readiness, prior-authorization friction, patient activation, and expected H2 cadence could influence estimates materially.
Novo Nordisk has sought to block certain Lilly advertising for Zepbound and Mounjaro, alleging misleading comparisons. Lilly disputes the claims. This appears unlikely to be a near-term fundamental earnings issue, but it is a headline and commercial-execution risk worth monitoring.
LLY’s Q2 report is primarily a test of durability, not discovery. The company has already proved it can generate extraordinary growth; now it must demonstrate that its volume-led model remains intact as access broadens and net prices decline.
A strong outcome would be characterized by sustained tirzepatide demand, resilient international Mounjaro sales, early Foundayo traction, contained margin pressure, and a guidance raise or at least more confident H2 framing. The most important negative signal would be a widening gap between prescription growth and net sales growth—evidence that pricing concessions are beginning to outrun the incremental patient opportunity.